小细胞肺癌组织胸苷激酶表达临床意义的研究  

Expression and significance of thymidine-kinase 1 in small cell lung carcinoma tissues

作　　者：管燕[1] 郭其森[1] 山凤莲[2] 刘秀菊[1] 

机构地区：[1]山东省肿瘤医院内一科,山东济南250117 [2]山东省济宁医学院附属医院呼吸科,山东济宁272000

出　　处：《中华肿瘤防治杂志》2010年第10期746-748,共3页Chinese Journal of Cancer Prevention and Treatment

摘　　要：目的:探讨胸苷激酶1(TK1)在小细胞肺癌(SCLC)中的表达及临床意义。方法:利用增强化学发光法(ECLA)检测经病理确诊的36例小细胞肺癌患者不同分期及化疗前后血清TK1含量,同时检测19名健康查体者血清TK1含量。结果:SCLC患者血清TK1表达水平显著高于健康查体者(P<0.05)。SCLC广泛期患者较局限期患者的TK1表达水平高(P<0.05)。SCLC患者化疗前后进展组、稳定组、部分缓解组和完全缓解组血清TK1含量呈递减趋势,差异有统计学意义,P<0.05。结论:血清TK1浓度检测在SCLC患者的早期筛查、分期及疗效评估中具有较大的临床应用价值。OBJECTIVE：To investigate the expressions of serum thymidine kinase 1（TK1）in the small-cell lung cancer（SCLC）to find their clinical significance.METHODS：The serum level of TKl was determined by enhanced chemiluminescence assay（ECLA）in the SCLC patients stages,before chemotherapy,after two cycles of chemotherapy and normal controls.RESULTS：SCLC patients had a higher positive rate of TK1 than Health checkup（P〈0.05）.Extensive deadline patients had a higher positive rate of TK1 than that of localizated deadline patients（P〈0.05）.Serum TK1 levels of progress group,stable group,partial remission group,complete remission group in SCLC patients decreased before and after chemotherapy,and the difference was significan（P〈0.05）.CONCLUSION：In the SCLC patients the levels of TK1 has the relationship with the Clinical by stages,curative effect and prognosis.

关 键 词：癌 小细胞肺 肺肿瘤/病理学 胸苷激酶 

分 类 号：R734.2[医药卫生—肿瘤]